Create a narrative

Biofrontera Community

NasdaqCM:BFRI Community

1 Narratives written by author
0 Comments on narratives written by author
11 Fair Values set on narratives written by author

AN

AnalystConsensusTarget

AnalystConsensusTarget

Consensus Narrative from 2 Analysts

Pipeline Expansion And Label Extension Will Broaden Treatment Options

Key Takeaways Exclusive product formulations, regulatory approvals, and expanding clinical indications support strong pricing, stable margins, and significant future revenue growth. Operational efficiencies, innovative launches, and targeted R&D investments improve profitability and competitive positioning in a growing dermatology market.

US$6.38

FV

85.6% undervalued

23.62%

Revenue growth p.a.

0

0

8

4 days ago